terbinafine hydrochloride
RxCUI 235838
Medication research snapshot
CureCurrent currently links 1 distinct registered clinical trials to terbinafine hydrochloride through its RxNorm intervention mappings. 0 of those studies have the registry status “recruiting” (0%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.
The leading sponsor shown in this linked dataset is Novartis, associated with 1 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.
The highest-count mapped research city in the current result is Chicago, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.
The most common trial-reported condition associated with this drug concept is Candidiasis, Oral (1 linked trials). A registry intervention association is not proof that a drug is approved or effective for that condition.
Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.
Understanding this RxNorm record
RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.
Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.
Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Terbinafine
Terbinafine, sold under the brand name Lamisil among others, is an antifungal medication used to treat pityriasis versicolor, fungal nail infections, and ringworm including jock itch and athlete's foot. It is either taken by mouth or applied to the skin as a cream or ointment. Common side effects when taken by mouth include nausea, diarrhea, headache, cough, rash, and elevated liver enzymes. Severe side effects include liver problems and allergic reactions. Liver injury is, however, unusual. Oral use during pregnancy is not typically recommended. The cream and ointment may result in itchiness but are generally well tolerated. Terbinafine is in the allylamines family of medications. It works by decreasing the ability of fungi to synthesize ergosterol. It appears to result in fungal cell death. Terbinafine was discovered in 1991. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 253rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
1 shownConditions being studied
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.